表皮生长因子受体和蛋白激酶B在胃癌组织中的表达及临床意义

目的探讨胃癌组织表皮生长因子受体（EGFR）和蛋白激酶B（AKT）在胃癌组织中的表达与胃癌临床病理特征及预后的关系。方法采用免疫组织化学方法检测84例胃癌组织和15例非癌胃组织中EGFR和AKT的表达情况,并分析其表达与胃癌患者临床病理特征及预后的关系。结果EGFR和AKT在胃癌组织的阳性表达率分别为55．9％（47／84）和64．3％（54／84）,明显高于非癌胃组织的20．0％（3／15）和6．7％（1／15）,差异均有统计学意义（P〈0．05,P〈0．01）。EGFR表达与胃癌分期有关,AKT表达则与胃癌淋巴结转移有关（均P〈0．01）。EGFR阴性表达和阳性表达患者5年总体生存率分别为49％和22％（P〈0．05）;AKT阴性表达和阳性表达患者5年总体生存率分别为45．7和30．2％（P〈0．05）。结论检测胃癌组织中的EGFR和AKT的表达,有助于判断胃癌恶性程度及评估预后。     

胃癌组织中Omi/HtrA2的表达及与预后的关系

目的 探讨丝氨酸蛋白酶Omi/HtrA2在胃癌组织中的表达及其与胃癌临床病理特征及预后的关系.方法 采用免疫组化法检测68例胃癌组织、15例癌旁组织及15例正常胃黏膜组织中Omi/HtrA2的表达,并分析其表达与胃癌临床病理特征及预后的关系.结果 Omi/HtrA2在胃癌组织中的阳性表达率为73.5%（50/68）,高于癌旁组织（13.3%,2/15）和正常胃黏膜（6.7%,1/15）,差异有统计学意义（P＜0.05）.胃癌组织中Omi/HtrA2的表达与患者的性别、年龄、肿瘤大小及浸润深度无关（P＞0.05） 与肿瘤的分化程度、淋巴结转移和临床分期有关（P＜0.05）.本组胃癌患者5年总体生存率为63.3%,其中Omi/HtrA2表达阳性组和阴性组分别为72.0%和61.1%,两组比较,差异并无统计学意义（P＞0.05）.结论 Omi/HtrA2在胃癌组织中高表达,其表达与胃癌分化程度、淋巴结转移及TNM分期有关,但并不影响胃癌患者的预后.     

HER-2基因表达水平与相同病理分期胃癌患者预后的关系

目的 研究HER-2基因在相同病理分期胃癌组织中的表达水平,探讨其作为判断胃癌患者预后指标的可行性.方法 应用免疫组化法检测110例患者胃癌标本中HER-2基因的表达水平,并结合患者病理分期及生存期进行统计学分析.结果 本组中HER-2基因的总的阳性表达率为33.64％(37/110).其中Ⅱ期胃癌组织中HER-2基因弱阳性表达率为21.31％(13/61),强阳性表达率为9.84％(6/61);Ⅲ期胃癌组织中HER-2基因弱阳性表达率为20.41％(10/49),强阳性表达率为16.33％(8/49).结合生存期进行统计学分析可知,相同病理分期胃癌组织中,HER-2基因表达阴性组生存率最高,弱阳性组次之,强阳性组最低,差异具有统计学意义(P＜0.01).结论 HER-2基因表达水平与相同病理分期胃癌患者预后有关,可作为判断胃癌生物学行为和预后的参考指标.     

PCNA蛋白在胃癌组织中的表达及其与预后的关系

目的：探讨PCNA蛋白在胃癌组织中的表达情况,并分析其与临床病理特征及预后的关系。方法：回顾性分析300例确诊并手术治疗的胃癌患者的病历资料,采用免疫组织化学SP法检测PCNA蛋白在胃癌组织及癌旁正常组织的表达,使用Kaplan-Meier法计算无复发生存率,评估PCNA蛋白与胃癌生物学特征及预后的关系。结果：癌旁正常组织中PCNA蛋白的阳性表达水平明显低于肿瘤组织（13.3%vs 36.7%,P〈0.05）。PCNA蛋白的表达与胃癌患者年龄、性别、肿瘤大小以及是否有远处转移等无明显相关性（P〉0.05）;而与病理组织的Lauren分型、肿瘤细胞的分化程度、是否有淋巴结转移以及TNM分期相关（P〈0.05）。Kaplan-Merier曲线显示,PCNA蛋白阳性表达患者的术后无复发生存率较阴性表达患者明显降低（P〈0.001）。结论：PCNA蛋白在胃癌组织中高表达,其高表达提示预后不良。     

E-cadherin和Slug在胃癌组织中的表达及意义

目的：探讨胃癌患者肿瘤组织中E-cadherin及Slug的表达与肿瘤病理特征及预后的关系。方法：免疫组化检测82例胃癌患者瘤组织E-cadherin及Slug的表达,并分析它们与患者的病理特征及生存时间的关系。结果：E-cadherin保留表达率为47.6%,Slug阳性表达率为39.0%。E-cadherin的表达率差异与患者的N分期有关,Slug的阳性表达率差异与患者的性别、T分期及N分期有关（均P<0.05）;在E-cadherin表达保留组,Slug的表达与N分期、M分期、静脉侵袭、血行性转移和腹膜复发有关,而在E-cadherin表达降低组,Slug的表达与T分期有关（均P<0.05）;E-cadherin表达保留患者5年生存率高于E-cadherin表达降低患者（79.5% vs. 60.5%）,Slug阳性患者的5年生存率低于Slug阴性患者（59.4% vs. 74.0%）（均P<0.05）;E-cadherin表达保留组中,Slug阳性患者5年生存率低于阴性患者分别为（48.4% vs. 87.5%）（P<0.05）,而E-cadherin表达降低组中,Slug阳性及阴性患者生存率无统计学差异（58.3% vs. 68.4%）（P>0.05）。结论：E-cadherin及Slug的表达主要与胃癌TNM分期有关;E-cadherin表达保留的患者中Slug的阳性表达对不良预后有预测意义。

     

HER-2/neu蛋白表达与胃癌临床病理特征及预后关系的研究

探讨胃癌组织中人表皮生长因子受体(HER)-2/neu蛋白的表达与患者临床病理特征及预后的关系。选取本院肿瘤科收治的98例胃癌确诊患者肿瘤组织标本及40例患者癌旁组织行免疫组化染色,观察两种组织标本中HER-2/neu蛋白表达情况,并分析其与胃癌患者临床病理特征和预后的关系。胃癌组织中HER-2/neu蛋白阳性表达率显著高于癌旁组织(38.78%比0,P0.05)。胃癌组织中HER-2/neu蛋白阳性表达主要与肿瘤淋巴结转移、远处转移、浸润深度、TNM分期、Lauren分型有关(P0.05)。HER-2/neu蛋白阴性表达患者的3年生存率显著高于阳性表达患者(58.33%比28.95%,χ~2=8.066,P0.05)。胃癌组织HER-2/neu蛋白阳性表达患者的中位生存时间显著低于阴性表达患者(17.9个月比28.6个月,χ~2=10.565,P0.05)。胃癌组织中HER-2/neu蛋白的表达与患者临床病理特征及远期预后密切相关。     

Her-2/neu表达对无淋巴结转移早期胃癌患者预后的影响

目的：探讨Her-2/neu表达及临床病理特征对无淋巴结转移的早期胃癌患者预后的影响。 方法：收集70例有完整随访记录和病理组织蜡块保存完整的无淋巴结转移的早期胃癌根治手术切除患者资料,采用免疫组化法检测病理组织切片Her-2/neu表达情况,分析Her-2/neu表达及临床病理因素与患者预后的关系。 结果：全组Her-2/neu阳性表达率为25.0%,Her-2/neu表达与患者的性别、年龄、肿瘤大小、分化类型及浸润深度均无明显关系（均P>0.05）。全组5年生存率为87.8%。单因素分析显示,患者性别、年龄、肿瘤大小、肿瘤浸润深度及分化程度对患者生存状况无明显影响（均P>0.05）。Her-2/neu表达阳性患者的5年生存率72.0%,阴性患者为93.0%,差异有统计学意义（P<0.05）。多因素回归分析显示,Her-2/neu的表达为影响预后的危险因素（OR=5.036,P=0.035）。 结论：Her-2/neu的表达是影响无淋巴结转移早期胃癌患者预后的危险因素,并对早期胃癌的临床治疗有一定指导意义。     

非小细胞肺癌患者中B细胞淋巴瘤-2、人体第二表皮生长因子受体蛋白表达的比较研究

目的 研究非小细胞肺癌（NSCLC）患者B细胞淋巴瘤-2（Bcl-2）、人体第二表皮生长因子受体（Her-2）蛋白的表达情况及临床意义.方法 应用组织芯片、免疫组化技术检测208例NSCLC患者的肿瘤组织、150例癌旁组织以及17例良性肺疾病肺组织中的Bcl-2、Her-2蛋白的表达情况.结果 ①NSCLC癌组织中Bcl-2蛋白表达率明显高于癌旁组织及肺良性疾病肺组织（ P〈0.05）;Bcl-2蛋白表达水平与NSCLC临床分期及淋巴结转移有相关性（P〈0．05）.②NSCLC癌组织中Her-2蛋白的表达率明显高于癌旁组织及肺良性疾病肺组织（P〈0.05）;Her-2蛋白表达水平与NSCLC分化程度差异有统计学意义（P〈0．05）.结论 ①Bcl-2、Her-2蛋白在NSCLC组织中均高表达,提示Bcl-2及Her-2基因的表达异常与NSCLC的发生发展密切相关;②Bcl-2蛋白表达程度与NSCLC的临床分期及淋巴结转移有关,Her-2蛋白表达程度与NSCLC的分化程度有关,提示两者均与肿瘤恶性生物学行为密切相关.     

pT1-4aN0M0胃癌淋巴结微转移检测的临床意义

目的：探讨淋巴结微转移及临床病理因素对 pT1-4aN0M0期胃癌患者术后5年无瘤生存率的影响。 方法：纳入2008年1月—9月期间pT1-4aN0M0期胃癌患者行根治术者45例849枚HE染色阴性淋巴结,应用免疫组化法检测这些淋巴结中CK19表达,观察其淋巴结发生微转移情况,并分析发生微转移胃癌患者的临床病理特征及微转移的发生对患者5年无瘤生存率的影响。 结果：经免疫组化染色,849枚HE常规染色阴性淋巴结中CK19阳性表达率为8.13%（69/849）;有31.11%（14/45）患者的淋巴结CK19表达阳性。术后随访时间13~69个月（平均随访时间55.08个月）,淋巴结中CK19阴性表达、阳性表达患者的5年总生存率分别为83.87%、42.86%;两者无瘤生存率差异有统计学意义（χ2=9.112,P=0.003）。淋巴结CK19阳性表达与胃癌患者的肿瘤直径（P=0.007）、浸润胃壁深度（P=0.032）有关,5年无瘤生存率与临床病理因素无关（P>0.05）。Cox生存回归分析显示淋巴结微转移为独立预后因素,14例患者被检测出微转移,建议重新分期,重新分期率为31.11%（14/45）。 结论：胃癌pT1-4aN0M0期患者,免疫组化染色能检出常规HE染色阴性淋巴结中的微转移,有助于细化分期、判断预后及指导治疗。     

基质金属蛋白酶9在胰腺癌组织中的表达及其临床意义

目的探讨胰腺癌组织中基质金属蛋白酶9（MMP-9）的表达及其与临床病理指标和预后的关系。方法应用免疫组织化学EliVisionTMPlus法检测70例手术切除的原发性胰腺癌组织及15例癌旁无瘤胰腺组织中MMP-9的表达,并分析患者生存率、临床病理资料与MMP-9表达水平的关系。结果 MMP-9在70例原发性胰腺癌组织中的阳性率为68.6%（48/70）,而在15例癌旁无瘤胰腺组织中的阳性率为26.7%（4/15）,两者差异有统计学意义（χ2=9.13,P〈0.05）;MMP-9表达与性别、年龄及肿瘤部位无关,与肿瘤大小、分化程度、TNM分期、淋巴结转移显著相关（P〈0.05）。MMP-9表达阴性的22例患者术后无进展生存率与总体生存率均明显长于MMP-9阳性的48例患者（χ2分别为11.84和16.09,P〈0.05）。结论 MMP-9的表达与胰腺癌的临床病理指标密切相关,其高表达提示患者预后不良。     

Expression of Her-2 in carcinomas of the esophagus

The human epidermal growth factor receptor-2 gene (HER-2) encodes for a membrane-bound tyrosine kinase (Her-2), which is overexpressed in various human cancers. Her-2-targeted therapy has recently been shown to be beneficial for patients with advanced gastric cancer. Her-2 protein expression was investigated in 341 esophageal carcinomas [152 squamous cell carcinomas (SCC), 189 adenocarcinomas (AC)], 39 cases of Barrett mucosa, and 11 cases of squamous cell dysplasia. HER-2 gene amplification was assessed by colorimetric in-situ hybridization. Positive Her-2 status was found in 15.3% of ACs and 3.9% of SCCs. Positive Her-2-status was more common in dysplastic Barrett mucosas compared with nondysplastic ones (P=0.04). In 26% of the patients with ACs who had received neoadjuvant chemotherapy (n=39), the Her-2 status of pretherapeutic biopsies was different compared with subsequent surgical specimens. There was no statistically significant correlation between Her-2 status and patients' survival. Although Her-2 overexpression is rare in SCCs, it is found in 15.3% of ACs, where amplification of HER-2 gene and overexpression of Her-2 protein seem to be early events in carcinogenesis. The evaluation of Her-2 status in tumor biopsies and in particular in the context with possible alterations after neoadjuvant treatment can potentially lead to false Her-2-staging. Although Her-2-overexpression in esophageal cancer seems to have no influence on patients' survival, these subtypes of esophageal ACs have to be considered as targets for an anti-Her-2 therapy.     

Clinicopathologic significance of Her-2 and P53 expressions in gastric cancer

BackgroundTo detect the expression of HER-2 and P53 patients with gastric cancer and to analyze their correlation.MethodsA total of 249 gastric cancer patients with complete clinical data who received surgical treatment from China–Japan Union Hospital of Jilin University were selected. The expression of Her-2 and P53 were detected by immunohistochemistry using the streptavidin-biotin-peroxidase method. The correlations between HER-2 and P53 in gastric cancer were analyzed.ResultsThe positive rate of Her-2 and P53 expression was 37.3% (93/249) and 100% in all the specimens, respectively. The intensity of Her-2 expression was significantly different in patients with different degrees of gastric cancer cell differentiation (P = 0.012). Meanwhile, the expression of her-2 was closely related to whether the pathological type of gastric cancer was a signet-ring cell carcinoma (P = 0.022). Different percentage of positive P53 expression was closely related to the grade of tumor differentiation (P = 0.035) and positive Ki67 expression (P = 0.001). There was a significant positive correlation between HER-2 and P53 expression in gastric cancer (P = 0.003). These findings suggest that HER-2 and P53 have synergistic effects in gastric cancer.ConclusionHer-2 and P53 are important markers for invasion and metastasis of gastric cancer. Combined detection of P53 and Her-2 expression in gastric cancer tissue can be used to assess prognosis and screen cancer patients at high risk of metastasis.     

Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer

BACKGROUND: Amplification and mutation of the epidermal growth factor receptor (EGFR) and Her-2 genes were analyzed in both hormone sensitive and hormone refractory prostate cancer (HRPC). METHODS: Gene amplifications of EGFR and Her-2 were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on a total of 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of EGFR and exons 19 and 20 of Her-2. Amplification and mutation were compared with clinicopathologic features. RESULTS: Gene amplification of EGFR was observed in 6 (30%) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient, with hormone refractory status, had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer but were not associated with the ductal type. No significant correlation was found between mutation change and hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (P = 0.017). There were no Her-2 gene amplifications or mutations found in any of the samples. CONCLUSIONS: EGFR gene mutation and amplification occurred frequently in advanced prostate cancer cases. EGFR mutations do not appear to play a significant role in the hormone refractory pathway but are associated with prognosis.     

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma

The purpose of this study was to determine if any relationship exists between Her-2/neu gene amplification and estrogen receptor (ER), progesterone receptor (PR), MIB-1, grade, size and age in female breast cancer. Five hundred and eighteen female patients with invasive breast carcinoma, 390 ductal and 128 lobular, in which assessment of Her-2/neu amplification by fluorescence in-situ hybridization (FISH) has been performed, were reviewed retrospectively. Each patient was further assessed for ER, PR, MIB-1, grade, size and age at diagnosis. Chi-square analysis was then used to correlate the above observations. Overall gene amplification was seen in 76 (15%) of the cases, 68 (17%) were ductal and 8 (6%) were lobular. Her-2/neu gene was amplified in 37 (10%) out of 379 ER positive cases and in 39 (28%) out of 139 ER negative cases. Her-2/neu was amplified in 22 (7%) out of 301 PR positive cases and in 54 (25%) out of 217 PR negative cases. Amplification occurred in 18 (8%) out of 222 negative MIB-1 cases and amplified in 58 (20%) out of 296 positive cases. Amplification was seen in 5 (10%) out of 49 grade I tumors, 17 (12%) out of 143 grade II tumors and 54 (27%) out of 198 grade III tumors. Lobular carcinomas were not graded. Amplification was present in 52 (15%) out of 346 T1 lesions, in 17 (13%) out of 130 T2 lesions, in 5 (17%) out of 30 T3 lesions and in 2 (17%) out of 12 T4 lesions. Her-2/neu was amplified in 67 (14%) out of 467 woman 41 years and older, and in 9 (18%) out of 51 women 40 years and younger. Comparison of these frequencies using chi-square test revealed statistically significant correlation between Her-2/neu amplification and ductal versus lobular carcinoma (p<0.0003), ER (p=0.0001) and PR (p<0.0001) negative tumors, over-expression of MIB-1 (p<0.0005) and high tumor grade (p=0.0009), while size of the tumor (p=0.08) and age of the patients (p=0.67) were not statistically significant. Correlation was found between Her-2/neu amplification and tumor type, high histological grade, ER and PR negative tumors, and high proliferative MIB-1 index. No correlation was found between size of the tumor and age of the patient with Her-2/neu amplification.     

Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy

Purposes

The trastuzumab for Gastric Cancer study newly defined tumors that were positive for human epidermal receptor-2 (Her-2) and created a Her-2-oriented treatment strategy that is also applicable in the adjuvant setting for stage 2/3 cancers. However, there is currently no information available on the rate of Her-2 positivity and the relapse-free survival (RFS) stratified by Her-2 status in stage 2/3 patients.

Methods

The Her-2 status, defined by the current standard method, was examined in 100 gastric cancer patients who underwent curative D2 surgery, who were pathologically diagnosed with stage 2/3 cancer, and received adjuvant S-1 chemotherapy between June 2002 and December 2011.

Results

Ten of the 100 patients were Her-2 positive. Her-2-positive status was more frequently seen in tumors with a differentiated histology. The 5-year RFS rate was 56.3 % in Her-2-positive cases, and 48.8 % in Her-2 negative cases, which was not significantly different (P = 0.786).

Conclusions

The Her-2-positive rate for stage 2/3 gastric cancer patients was low, at only 10 %. Although the RFS was not significantly different based on the Her-2 status, the low positive rate made interpretation difficult. A multi-center study with a large sample size is necessary to clarify the prognostic impact of Her-2 in stage 2/3 gastric cancer patients.     

胃癌HER2蛋白表达及基因扩增分析

目的 探讨胃癌组织HER2蛋白表达和基因扩增情况及其临床意义.方法 收集2011年4月至2012年5月间青岛大学医学院附属医院黄岛院区收治的80例胃癌标本,采用免疫组织化学染色（IHC）和显色原位杂交（CISH） 方法检测HER2蛋白表达和基因扩增情况,分析其与临床病理因素的相关性.结果 80例患者中,HER2蛋白表达（-）51例,（＋）12例,（＋＋）12例,（＋＋＋）5例,阳性表达率为21.3％（17/80）;HER2基因扩增 4例,临界扩增3例,基因扩增率为8.8％（7/80）.IHC和CISH检测结果呈正相关（P＜0.05）,两者的符合率为85.0％（68 /80）.HER2表达与肿瘤部位、分化程度及TNM分期有关（均P＜0.05）.结论 胃癌组织中有较高的HER2蛋白表达和基因扩增率,其与胃癌的发生发展密切相关.     

Ki-67在T1期乳腺癌中的表达及其与Her-2和ER的关系

目的 研究Ki-67在T1期乳腺癌的表达情况,以及其与雌激素受体(ER)、人表皮生长因子受体-2(Her-2)的关系,指导早期乳腺癌的预后判断.方法 选择2008年1月至2011年6月的女性新发T1期乳腺癌组织共60例,免疫组化检测Ki-67的表达情况,并分析其表达与临床病理特征和Her-2、ER表达的关系.结果 60...     

长链非编码RNA-linc00092在胃癌组织的表达及其临床意义

目的观察长链非编码RNA(lncRNA)-linc00092在胃癌组织中的分布特点,探讨linc00092表达高低对胃癌患者多种生存特点的影响,并对其与胃癌常见临床病理学特点的相关性进行分析。方法在13例胃癌患者中,分析癌组织和正常组织中的linc00092的表达差异;在线生存数据库中,分析胃癌组织中的linc00092表达水平对胃癌患者总生存(OS)、疾病进展后生存(PPS)、首次进展后生存(FP)的影响;收集90例胃癌患者癌组织新鲜冰冻组织标本,行实时定量聚合酶链反应(Real-time PCR)检测linc00092水平,分析癌组织中的linc00092与胃癌患者常见临床病理特点的关系。采用χ²检验或者Fisher′s确切概率法分析。结果13对胃癌组织和正常组织中,linc00092的表达水平在胃癌组织的表达水平是胃正常组织中的2.316倍(t=3.195,P<0.05),差异有统计学意义;linc00092高表达的胃癌人群的OS在数据库胃癌总体人群、Ⅲ~Ⅳ期胃癌患者、女性患者、男性患者、仅接受手术患者、人表皮生长因子受体2(Her-2)阴性和阳性患者中明显低于linc00092低表达者(P<0.05);linc00092高表达的胃癌人群的FP在总体人群、Ⅱ~Ⅲ期胃癌患者、Her-2阴性和阳性患者中显著低于linc00092低表达组(P<0.05),差异均有统计学意义;linc00092高表达的胃癌人群的PPS在总体人群、Ⅰ~Ⅳ期胃癌患者、女性和男性患者、仅接受手术患者、Her-2阴性和阳性患者中显著低于linc00092低表达组(P<0.05),差异均有统计学意义;胃癌中的linc00092的表达水平越高,癌组织分化越差(P<0.05),肿瘤越容易出现淋巴结转移(P<0.05)、更容易出现深部浸润(P<0.05),差异均有统计学意义。结论较高的linc00092提示胃癌患者预后较差,同时linc00092在胃癌组中显著高表达,和患者的组织学分级、浸润深度和淋巴结转移情况明显相关。     

Ki-67、P53在Her-2阴性乳腺癌中的表达与ER、腋窝淋巴结转移相关性

目的观察Ki-67、P53在Her-2阴性乳腺癌组织中的表达与ER及腋窝淋巴结转移相关性,探讨其临床意义,提示乳腺癌预后。方法 202例Her-2阴性乳腺患者,根据ER表达情况,将患者分为ER阴性组和ER阳性组,其中ER阴性组99例,ER阳性组103例,研究Ki-67、P53在Her-2阴性乳腺癌组织中的表达与ER及腋窝淋巴结转移相关性。结果 Her-2阴性乳腺癌组织中Ki-67增殖指数在ER阴性组表达明显高于ER阳性组,差异有统计学意义(P0.05),Ki-67增殖指数在腋窝淋巴结阳性组明显高于淋巴结阴性组,差异有统计学意义(P0.05)。P53在ER阴性组表达明显高于ER阳性组,差异有统计学意义(P0.05),P53表达在腋窝淋巴结阳性组和阴性组差异无统计学意义(P0.05)。结论 Her-2阴性乳腺癌组织中Ki-67增殖指数与ER阴性表达正相关,且腋窝淋巴结转移可能性大,P53与ER阴性表达正相关,与腋窝淋巴结转移无明显相关。提示Ki-67、P53可能为Her-2阴性乳腺癌的不良预后因素。     

High-throughput tissue microarray analysis of erbB-2 gene amplification in urinary bladder cancer. A study of Bulgarian patients

INTRODUCTION: Overexpression of the receptor Her-2 leads to increased proliferative response to epidermal growth factors which plays a key role in tumor development and growth. Increased oncoprotein level, in the majority of cases, is caused by erbB-2 gene amplification. To define the frequency of amplifications of erbB-2 in bladder cancer, and to determine their association with the tumor phenotype we utilized tissue microarray (TMA) approach. MATERIALS AND METHODS: We analyzed a TMA consisting of 159 transitional cell bladder carcinomas for erbB-2 gene amplification by dual-color FISH. RESULTS: The frequency of erbB-2 amplification was 5.3% of all successfully analyzed samples (4 of 75). It increased from minimally invasive (pT1) to muscle-invasive (pT2-4) tumors, as well as with advanced tumor grade (G1 to G2 to G3). All amplifications were cluster amplifications confirming the fact that erbB-2 amplification occurs intrachromosomally in bladder cancer. CONCLUSIONS: We concluded that despite its low incidence, erbB-2 amplification is of importance for the bladder tumor invasion and progression.